Education
About Us
Working with TipRanks
Follow Us
Cellebrite DI (CLBT)
NASDAQ:CLBT
Top Page
Cellebrite DI
(NASDAQ:CLBT)
57Neutral
Positive Factors
Financial Performance
Cellebrite reported fourth-quarter results above consensus, indicating strong performance.
Growth Prospects
There is a tremendous cross-sell opportunity as customers migrate from legacy technology to the new C2C platform.
Market Position
Cellebrite is confident it remains the preferred vendor over its competitor due to the strength of its end-to-end solutions.
Negative Factors
Leadership Uncertainty
The company is actively searching for its next permanent CEO, which adds uncertainty to leadership stability.
Market Reaction
Shares are likely down on profit-taking, some U.S. federal deals getting pushed to the right, and the 2025 margin guidance that implies modest contraction.
Political Impact
Modest Political Headwinds – Cellebrite gave a healthy guide for Q1'25, but it would have been higher had the business not been impacted by regime change in certain countries.
Cellebrite DI (CLBT) vs. S&P 500 (SPY)
Market Cap
$4.94B
Dividend YieldN/A
Average Volume (3M)2.06M
Price to Earnings (P/E)―
Beta (1Y)1.30
Revenue Growth23.41%
EPS Growth-222.82%
CountryUS
Employees1,008
SectorTechnology
Sector Strength54
IndustrySoftware
Share Statistics
EPS (TTM)-1.40
Shares Outstanding239,470,060
10 Day Avg. Volume1,203,097
30 Day Avg. Volume2,058,124
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)15.10
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$27.80Price Target Upside39.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Cellebrite DI Business Overview & Revenue Model
Company DescriptionCellebrite DI Ltd. develops solutions for legally sanctioned investigations. Its DI platform allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations and solutions are used in a various case, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, intellectual property theft, and civil litigation. The company's Universal Forensic Extraction Device solution addresses problems in accessing digital information, including complicated device locks, encryption barriers, deleted and unknown content, and other obstacles that can prevent critical evidence from coming to light. It also offers Seeker solution that provides the ability to analyze video footage; OSINT Analyze, a real-time deep dive solution used to analyze open-source information, such as the surface web, deep web, and the dark web; and Crypto Tracer, which analyzes blockchain transactions together with related data from an extensive list of sources to identify and categorize wallets, and transactions. The company serves federal and state and local agencies, as well as enterprise companies and service providers. It has operations in the United States, Germany, Singapore, Australia, Brazil, United Kingdom, France, Canada, Japan, and India. The company was incorporated in 1999 and is based in Petah Tikva, Israel. Cellebrite Mobile Synchronization Ltd. operates as a subsidiary of Sun Corporation.
How the Company Makes MoneyCellebrite makes money through the sale of its proprietary digital intelligence software and hardware solutions. The company's revenue model is primarily based on licensing fees for its software products, which include data extraction tools and analytics platforms, as well as sales of hardware solutions designed for digital data collection. Additionally, Cellebrite offers subscription-based services for ongoing support, updates, and training, providing a steady stream of recurring revenue. Key revenue streams include contracts with law enforcement agencies, government entities, and private enterprises that require sophisticated digital forensics capabilities. Significant partnerships with technology firms and law enforcement organizations also contribute to its earnings by expanding its product reach and enhancing its service offerings.
Cellebrite DI Financial Statement Overview
Summary
Cellebrite DI demonstrates strong revenue growth and operational improvements. However, it faces challenges with profitability due to negative net income and historical negative equity. Despite these challenges, the company has robust cash flow generation, indicating operational stability.Income Statement
Cellebrite DI has shown consistent revenue growth with a significant increase from 2023 to 2024. The gross profit margin is strong, though the net profit margin is negative due to high expenses leading to net losses. The EBIT margin shows improvement, indicating operational efficiency in recent years. However, the EBITDA margin is negative, reflecting substantial non-operating expenses or adjustments.65
Positive
Balance Sheet
The company's debt-to-equity ratio is low, suggesting minimal reliance on debt financing. However, the negative stockholders' equity in 2021 could indicate financial instability during that period. The return on equity is not calculable due to negative equity in some years, and the equity ratio shows fluctuations, reflecting changes in the company's asset base and equity.55
Neutral
Cash Flow
Cellebrite DI exhibits strong cash flow generation with positive operating and free cash flows, which have grown over time. The free cash flow to net income ratio is not favorable due to the net losses. However, the operating cash flow to net income ratio suggests that the company is generating sufficient cash from operations despite the net losses, indicating good cash flow management.70
Positive
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 401.20M | 325.11M | 270.65M | 246.25M | 194.91M | Gross Profit |
| 338.61M | 271.88M | 219.91M | 203.69M | 157.03M | EBIT |
| 56.91M | 33.24M | 1.04M | 13.82M | 9.22M | EBITDA |
| -265.38M | -64.80M | 10.24M | 89.88M | 16.95M | Net Income Common Stockholders |
| -283.01M | -81.10M | 120.81M | 71.40M | 5.78M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 447.22M | 302.92M | 183.62M | 181.56M | 237.64M | Total Assets |
| 690.57M | 532.88M | 403.29M | 339.78M | 364.39M | Total Debt |
| 10.97M | 14.13M | 15.36M | 0.00 | 0.00 | Net Debt |
| -180.69M | -175.39M | -72.29M | -145.97M | -128.71M | Total Liabilities |
| 354.55M | 498.67M | 329.43M | 413.13M | 300.58M | Stockholders Equity |
| 336.02M | 34.21M | 73.86M | -73.35M | 63.80M |
| Cash Flow | Free Cash Flow | |||
| 118.27M | 94.14M | 11.49M | 27.94M | 60.33M | Operating Cash Flow |
| 126.84M | 102.06M | 20.58M | 36.05M | 66.51M | Investing Cash Flow |
| -149.47M | -22.54M | -91.23M | 45.23M | -6.45M | Financing Cash Flow |
| 25.99M | 21.77M | 13.97M | -68.40M | -8.59M |
Cellebrite DI Technical Analysis
Neutral
19.95
Price Trends
20.97
Negative
20.63
Negative
17.87
Positive
Market Momentum
-0.14
Negative
51.49
Neutral
76.60
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLBT, the sentiment is Neutral. The current price of 19.95 is above the 20-day moving average (MA) of 18.50, below the 50-day MA of 20.97, and above the 200-day MA of 17.87, indicating a neutral trend. The MACD of -0.14 indicates Negative momentum. The RSI at 51.49 is Neutral, neither overbought nor oversold. The STOCH value of 76.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CLBT.
Cellebrite DI Peers Comparison
Overall Rating
UnderperformOutperform
Sector (58)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $78.50B | 44.69 | 338.74% | ― | 12.27% | 54.69% | |
73 Outperform | $4.71B | 27.73 | 41.09% | ― | 10.40% | 14.78% | |
67 Neutral | $17.23B | 1,777.39 | -5.91% | ― | 33.10% | -20.31% | |
63 Neutral | $4.42B | ― | -9.73% | ― | 12.68% | 54.80% | |
58 Neutral | $21.97B | 10.63 | -18.43% | 2.40% | 4.67% | -24.47% | |
57 Neutral | $4.94B | ― | -152.88% | ― | 23.41% | -222.82% | |
56 Neutral | $4.73B | ― | -20.26% | ― | 10.38% | 6.88% |
* Technology Sector Average
Performance Comparison
CLBT
Cellebrite DI
19.95
8.87
80.05%
FTNT
Fortinet
99.54
31.23
45.72%
QLYS
Qualys
129.06
-37.81
-22.66%
VRNS
Varonis Systems
41.69
-5.48
-11.62%
CYBR
CyberArk Software
348.42
82.79
31.17%
TENB
Tenable Holdings
35.96
-13.47
-27.25%
Cellebrite DI Earnings Call Summary
Earnings Call Date: Feb 13, 2025 | % Change Since: -19.94% | Next Earnings Date: May 8, 2025
Earnings Call Sentiment Positive
The earnings call reflects a positive performance with strong revenue, ARR growth, and cash flow metrics. While there are some challenges in the US federal sector and from market exits, the company anticipates these will be short-term issues. The achievements in revenue, cloud-based ARR, and FedRAMP status outweigh the lowlights.Highlights
Exceeded Revenue and Adjusted EBITDA Targets
Cellebrite exceeded original revenue and adjusted EBITDA targets for 2024 and delivered at the higher end of ARR expectations. ARR grew 25% year-over-year to $396 million.
Strong Free Cash Flow
Achieved $122 million in free cash flow in 2024, indicating solid cash generation capabilities.
Rule of 50 Performance
Delivered a Rule of 50 performance with 25% ARR growth and 25% adjusted EBITDA margins.
Increased Cloud-Based ARR
ARR from cloud-based offerings nearly doubled to 17% of total ARR in 2024.
FedRAMP-Ready Status
Achieved FedRAMP-ready status at a high-level designation, opening future opportunities within the US federal sector.
Lowlights
Federal Sector Headwinds
Faced modest headwinds from regime changes causing delays in US federal sector purchasing activity.
Impact from Exiting Certain Markets
Exiting certain countries is expected to modestly impact first-quarter results, though it contributed to improved gross retention.
Company Guidance
During the Cellebrite Fourth Quarter and Full Year 2024 Financial Results Conference Call, the company provided guidance for 2025, highlighting several key metrics. For the full year 2025, Cellebrite anticipates ARR growth between 21% and 25%, reaching $480 million to $495 million. Revenue is projected to increase by 20% to 22%, amounting to $480 million to $490 million. The company aims for adjusted EBITDA in the range of $113 million to $123 million, maintaining a margin of 24% to 25%. The guidance also emphasized the continuation of strong performance in subscription services, with expectations for further growth in their cloud-based solutions and increased penetration of their Guardian and Pathfinder products. The company plans to focus on sustaining top-line growth and enhancing profitability and free cash flow in the upcoming year.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.